Ptc Therapeutics (PTCT) Receivables (2013 - 2026)

Ptc Therapeutics' Receivables history runs 14 years deep, the most recent figure standing at $219.9 million for Q1 2026.

• In Q1 2026, Receivables rose 4.48% year-over-year to $219.9 million; the TTM figure through Mar 2026 stood at $219.9 million (up 4.48% YoY), while the FY2025 annual figure was $181.6 million, up 14.55% from the prior year.
• Receivables was $219.9 million for Q1 2026 at Ptc Therapeutics, up from $181.6 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $219.9 million in Q1 2026 to a low of $124.5 million in Q3 2022.
• Historically, Receivables has averaged $177.7 million across 5 years, with a median of $181.6 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Receivables jumped 72.51% in 2022, then decreased 1.69% in 2024.
• A 5-year view of Receivables shows it stood at $155.6 million in 2022, then grew by 3.48% to $161.0 million in 2023, then declined by 1.53% to $158.6 million in 2024, then gained by 14.55% to $181.6 million in 2025, then gained by 21.09% to $219.9 million in 2026.
• The last three Receivables figures came in at $219.9 million (Q1 2026), $181.6 million (Q4 2025), and $203.1 million (Q3 2025), per Business Quant data.